Potential new eye tumor treatment discovered

New research from a team including several Carnegie scientists demonstrates that a specific small segment of RNA could play a key role in the growth of a type of malignant childhood eye tumor called retinoblastoma. The tumor is associated with mutations of a protein called Rb, or retinoblastoma protein. Dysfunctional Rb is also involved with other types of cancers, including lung, brain, breast and bone. Their work, which will be the cover story of the August 15th issue of Genes & Development, could result in a new therapeutic target for treating this rare form of cancer and potentially other cancers as well.

MicroRNAs are a short, single strands of genetic material that bind to longer strands of messenger RNA--which is the courier that brings the genetic code from the DNA in the nucleus to the cell's ribosome, where it is translated into . This binding activity allows microRNAs to silence the expression of select in a targeted manner. Abnormal versions of microRNAs have been implicated in the growth of several types of cancer.

The paper from Carnegie's Karina Conkrite, Maggie Sundby and David MacPherson--as well as authors from other institutions—focuses on a cluster of microRNAs called miR-17~92. Recent research has shown that aberrant versions of this cluster are involved in preventing pre-cancerous cells from dying and allowing them to proliferate into tumors. Previous work has shown that miR-17~92 can be involved in the survival of lymphoma and leukemia cells by reducing the levels of a tumor-suppressing protein called PTEN.

The team's new research shows that miR-17~92 can also be involved in retinoblastoma, although it does not act in the same way, via the PTEN protein, as it does in other types of cancers. Rather, miR-17~92 acts to help cells that lack the tumor-suppressing Rb protein to proliferate.

First the team demonstrated that miR-17~92 is expressed in higher-than-usual quantities in all human retinoblastomas examined and in some mouse retinoblastomas. The authors engineered mice to express high levels of miR-17~92 in their retinas. When coupled with inactivation of Rb family members, expression of miR-17~92 led to extremely rapid and aggressive retinoblastoma. Then they showed that this abundance of miR-17~92 acts to suppress an inhibitor of proliferation, called p21Cip1, which is supposed to compensate for the loss of Rb.

"These findings— which show that miR-17~92 overcomes the cell's attempts to compensate for the loss of Rb—could be similar in other types of cancers," MacPherson said. "This microRNA cluster could represent a new therapeutic target for treating tumors caused by Rb deficiency."

Provided by Carnegie Institution

not rated yet

Related Stories

Silencing small but mighty cancer inhibitors

Dec 10, 2007

Researchers from Johns Hopkins and the University of Pennsylvania have uncovered another reason why one of the most commonly activated proteins in cancer is in fact so dangerous. As reported in Nature Genetics this week, ...

Why mice don’t get cancer of the retina

May 03, 2006

Humans are more susceptible to developing the eye cancer retinoblastoma than mice because, unlike humans, mice can compensate for the loss of activity of a gene critical to normal retinal development , according ...

Common cancer gene sends death order to tiny killer

May 31, 2007

Scientists at Johns Hopkins have discovered one way the p53 gene does what it's known for—stopping the colon cancer cells. Their report will be published in the June 8 issue of Molecular Cell.

Recommended for you

Pepper and halt: Spicy chemical may inhibit gut tumors

7 hours ago

Researchers at the University of California, San Diego School of Medicine report that dietary capsaicin – the active ingredient in chili peppers – produces chronic activation of a receptor on cells lining ...

Expressive writing may help breast cancer survivors

9 hours ago

Writing down fears, emotions and the benefits of a cancer diagnosis may improve health outcomes for Asian-American breast cancer survivors, according to a study conducted by a researcher at the University of Houston (UH).

Taking the guesswork out of cancer therapy

15 hours ago

Researchers and doctors at the Institute of Bioengineering and Nanotechnology (IBN), Singapore General Hospital (SGH) and National Cancer Centre Singapore (NCCS) have co-developed the first molecular test ...

Brain tumour cells found circulating in blood

15 hours ago

(Medical Xpress)—German scientists have discovered rogue brain tumour cells in patient blood samples, challenging the idea that this type of cancer doesn't generally spread beyond the brain.

International charge on new radiation treatment for cancer

16 hours ago

(Medical Xpress)—Imagine a targeted radiation therapy for cancer that could pinpoint and blast away tumors more effectively than traditional methods, with fewer side effects and less damage to surrounding tissues and organs.

User comments